Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA ® (pembrolizumab) plus Trodelvy ® (sacituzumab govitecan-hziy) reduced the risk of disease ...

U.S. companies remain optimistic about future international expansion despite facing cost pressures, disrupted supply chains and ongoing uncertainty more acutely when compared to global peers ...

U.S. companies remain optimistic about future international expansion despite facing cost pressures, disrupted supply chains and ongoing uncertainty more acutely when compared to global peers, ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.